Computational Biology Market Segmentation:
Product Segment Analysis
Based on the product, the software segment in the computational biology market is projected to garner the highest share of 42.7% by the end of 2035. The segment’s growth is highly fueled by a surge in the demand for bioinformatic tools and AI-based drug discovery platforms. In this regard, notable players, such as Dassault BIOVIA and Schrödinger, are deliberately leading with cloud-based analytical solutions, as well as molecular modeling, which tends to diminish drug development timelines. Besides, open source tools, including Bioconductor, and commercial suites, such as NDAnexus, both effectively cater to diversified demands, ranging from genomics to precision medicine, thus are suitable for the segment’s upliftment.
Application Segment Analysis
Based on the application, the precision medicine segment in the computational biology market is expected to hold the second-highest share of 29.5% during the forecast timeline. According to an article published by NLM in December 2024, a clinical study was conducted by collecting 5,322 reports from the U.S. FDA reporting system, denoting patients who experienced more than 40% hospitalization, and death in more than 10% of cases. Therefore, to keep control of this, precision medicine exists to revolutionize healthcare through molecular technologies, such as microbiomics, metabolomics, proteomics, transcriptomics, and genomics. Additionally, by analyzing biological data researchers are able to recognize genetic markers, develop personalized treatment, and predict disease risk.
End user Segment Analysis
Based on the end user, the pharmaceutical companies segment in the market is predicted to hold the third-highest share of 25.8% during the forecast period. These companies have implemented AI to optimize the efficiency of their respective drug candidates. As per the November 2022 NLM article, these companies are focusing on drug discovery, clinical testing, and approval for production. This has been possible through target identification, lead discovery and optimization, and preclinical testing, accounting for USD 600 million to USD 800 million within 7 to 10 years. Besides, Phases I, II, and III account for USD 1.2 billion to USD 1.4 billion, thus suitable for the segment’s growth.
Our in-depth analysis of the computational biology market includes the following segments:
|
Segment |
Subsegments |
|
Product |
|
|
Application |
|
|
End user |
|
|
Technology |
|
|
Service |
|
|
Type |
|
